Aquestive Therapeutics (AQST)

Aquestive Therapeutics (AQST-Q) has faced significant challenges recently, with a staggering 43% decline in its stock price over the past month. The recent communication from the FDA, highlighting major deficiencies in their application for the Anaphylm drug, has cast serious doubts on the potential approval of this important product. The uncertainty surrounding this application has understandably shaken investor confidence, leading to a more cautious outlook from experts. Despite these setbacks, there remains a sliver of hope for AQST, as some believe there could still be a chance for approval, urging investors not to sell just yet, though an overall decline in confidence is evident among analysts.